202P The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti-PD-1 treatment in patients with non-small cell lung cancer

Abstract

PDC*lung01 (IMP) is a therapeutic cancer vaccine based on an irradiated plasmacytoid dendritic cell line loaded with HLA-A*02:01 restricted peptides (NY-ESO-1, MAGE-A3, MAGE-A4, Multi-MAGE-A, MUC1, Survivin and Melan-A) able to prime and expand peptide-specific CD8+ T cells in vitro and in vivo, and is synergistic with anti-PD-1 (Charles, 2020; Lenogue 2021). Stage II/IIIA (cohort A) or stage IV, PD-L1≥50% (cohort B; +pembrolizumab) non-small cell lung cancer (NSCLC) patients received weekly intravenous and subcutaneous IMP for 6 times at two dose levels.